Your session is about to expire
← Back to Search
Tiragolumab + Atezolizumab for Non-Small Cell Lung Cancer
Study Summary
This trial will test a new combo drug to see if it's more effective than current treatment for a certain type of lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a serious heart condition.I have not had a severe infection in the last 4 weeks.My lung cancer is advanced, cannot be surgically removed, and has been confirmed by lab tests.You have a positive test for HIV, active hepatitis B or C, or active tuberculosis.My blood and organs are functioning well.I agree to either not have sex or use birth control, and not donate sperm.My NSCLC has a specific mutation in the EGFR gene or an ALK fusion.My spinal cord compression hasn't been treated or stabilized for 2 weeks.I have had leptomeningeal disease.I frequently need procedures to remove excess fluid from my chest or abdomen.I haven't had any cancer other than NSCLC in the last 5 years, or if I did, it was not serious and was treated.I have a history of lung scarring or inflammation not caused by infections.I have high calcium levels that need ongoing treatment.I have pain from my cancer that isn't relieved by treatment.The level of PD-L1 in the tumor.I haven't had major surgery in the last 4 weeks.You are expected to live for at least 12 more weeks.I am fully active or can carry out light work.I have not received a live vaccine in the last 4 weeks.You have a disease that can be measured using a specific set of guidelines.I have brain metastases that are untreated or getting worse.I haven't had any systemic treatment for my advanced lung cancer.You have had an autoimmune disease in the past.You have had serious allergic reactions to certain types of medications made from animals or cells, or have allergies to specific components of atezolizumab.I have had a bone marrow or organ transplant in the past.
- Group 1: Placebo + Atezolizumab
- Group 2: Tiragolumab + Atezolizumab
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many medical facilities are presently executing this trial?
"11 different medical centres are currently recruiting for this trial, including the University of Kansas Medical Center in Westwood, Arizona Oncology Associates PC-HAL from Tempe and HCA Midwest Health in Kansas City. Additionally, there is a selection of other sites involved as well."
What medical ailments does Tiragolumab typically address?
"Tiragolumab is a common form of treatment for small cell lung cancer (SCLC). It may also be beneficial in managing postoperative symptoms and other malignant neoplasms, including non-small cell lung carcinoma."
What adverse reactions have been observed with Tiragolumab?
"Given the Phase 2 trial status, our team at Power gave Tiragolumab a score of 2 reflecting some safety data but no evidence in regards to efficacy."
Are recruitment efforts still underway for this research trial?
"Clinicaltrials.gov reports that this medical experiment, which was originally published on August 10th 2018, is no longer recruiting patients. Despite this fact, there are an estimated 2300 other studies looking for participants at the moment."
What is the enrollment figure for this experiment?
"Unfortunately, recruiting for this trial has been concluded. It was initially published on August 10th 2018 and its most recent update came out on November 11th 2022. If you are looking for similar studies, presently there are 1,949 trials seeking participants with lung cancer as well as 351 clinical investigations that actively involve Tiragolumab treatment."
Does this research mark the initial foray into this area?
"Tiragolumab has been the subject of 351 current studies in 74 countries and 1646 cities, dating back to a 2008 sponsored trial by Hoffmann-La Roche. Comprising of 720 participants, this Phase 2 drug approval stage was followed up with 18401 subsequent trials over the years."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger